These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 27708221)

  • 1. PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma.
    Yang H; Zhao X; Zhao L; Liu L; Li J; Jia W; Liu J; Huang G
    Oncotarget; 2016 Nov; 7(44):72131-72147. PubMed ID: 27708221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin Y binds and activates CDK4 to promote the G1/S phase transition in hepatocellular carcinoma cells via Rb signaling.
    Chen L; Wang X; Cheng H; Zhang W; Liu Y; Zeng W; Yu L; Huang C; Liu G
    Biochem Biophys Res Commun; 2020 Dec; 533(4):1162-1169. PubMed ID: 33039146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.
    Zhang B; Dong S; Li Z; Lu L; Zhang S; Chen X; Cen X; Wu Y
    J Transl Med; 2015 Nov; 13():349. PubMed ID: 26541651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27
    Tuo L; Xiang J; Pan X; Hu J; Tang H; Liang L; Xia J; Hu Y; Zhang W; Huang A; Wang K; Tang N
    J Exp Clin Cancer Res; 2019 Feb; 38(1):50. PubMed ID: 30717766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma.
    Jiang H; Zhu Y; Zhou Z; Xu J; Jin S; Xu K; Zhang H; Sun Q; Wang J; Xu J
    Cancer Med; 2018 Mar; 7(3):869-882. PubMed ID: 29441724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Notch1 is a potential therapeutic target for the treatment of human hepatitis B virus X protein-associated hepatocellular carcinoma.
    Sun Q; Wang R; Wang Y; Luo J; Wang P; Cheng B
    Oncol Rep; 2014 Feb; 31(2):933-9. PubMed ID: 24336972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
    Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
    Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
    Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
    Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metadherin-PRMT5 complex enhances the metastasis of hepatocellular carcinoma through the WNT-β-catenin signaling pathway.
    Zhu K; Peng Y; Hu J; Zhan H; Yang L; Gao Q; Jia H; Luo R; Dai Z; Tang Z; Fan J; Zhou J
    Carcinogenesis; 2020 Apr; 41(2):130-138. PubMed ID: 31498866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.
    Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN
    Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells.
    Jeon JY; Lee JS; Park ER; Shen YN; Kim MY; Shin HJ; Joo HY; Cho EH; Moon SM; Shin US; Park SH; Han CJ; Choi DW; Gu MB; Kim SB; Lee KH
    Oncol Rep; 2018 Jul; 40(1):536-544. PubMed ID: 29749478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressing the CDC37 cochaperone in hepatocellular carcinoma cells inhibits cell cycle progression and cell growth.
    Wang Z; Wei W; Sun CK; Chua MS; So S
    Liver Int; 2015 Apr; 35(4):1403-15. PubMed ID: 25098386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SMYD4 monomethylates PRMT5 and forms a positive feedback loop to promote hepatocellular carcinoma progression.
    Zhou Z; Chen Z; Zhou Q; Meng S; Shi J; Mui S; Jiang H; Lin J; He G; Li W; Zhang J; Wang J; He C; Yan Y; Xiao Z
    Cancer Sci; 2024 May; 115(5):1587-1601. PubMed ID: 38438251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogene RPA1 promotes proliferation of hepatocellular carcinoma via CDK4/Cyclin-D pathway.
    Wang J; Yang T; Chen H; Li H; Zheng S
    Biochem Biophys Res Commun; 2018 Apr; 498(3):424-430. PubMed ID: 29477843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.
    Luo Y; Gao Y; Liu W; Yang Y; Jiang J; Wang Y; Tang W; Yang S; Sun L; Cai J; Guo X; Takahashi S; Krausz KW; Qu A; Chen L; Xie C; Gonzalez FJ
    Hepatology; 2021 Oct; 74(4):1932-1951. PubMed ID: 33896016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DYNLL1 accelerates cell cycle via ILF2/CDK4 axis to promote hepatocellular carcinoma development and palbociclib sensitivity.
    Liu Y; Li Z; Zhang J; Liu W; Guan S; Zhan Y; Fang Y; Li Y; Deng H; Shen Z
    Br J Cancer; 2024 Jul; 131(2):243-257. PubMed ID: 38824222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
    Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
    J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules.
    Kuriyama S; Hitomi M; Yoshiji H; Nonomura T; Tsujimoto T; Mitoro A; Akahane T; Ogawa M; Nakai S; Deguchi A; Masaki T; Uchida N
    Int J Oncol; 2005 Aug; 27(2):505-11. PubMed ID: 16010434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
    AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
    Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy.
    Shimizu D; Kanda M; Sugimoto H; Shibata M; Tanaka H; Takami H; Iwata N; Hayashi M; Tanaka C; Kobayashi D; Yamada S; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
    Int J Oncol; 2017 Feb; 50(2):381-386. PubMed ID: 28101581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.